Entrada Therapeutics Q3 net income $35.5M; initiates Phase 1 for DMD candidate ENTR-601-44

Entrada Therapeutics, Inc.

2023-Q3 EPS reported $0.08 revenue$87,165,000

Net income of $35.5M in Q3 2023 vs net loss of $(25.1M) in Q3 2022, driven by $43.7M collaboration revenue.
Cash, cash equivalents and securities of $353.6M as of Sep 30, 2023; runway expected through 2025.
Dosed first participant in Phase 1 trial of ENTR-601-44 for Duchenne muscular dystrophy; data expected H2 2024.
Selected third Duchenne candidate ENTR-601-50 with IND/CTA planned for 2025; preclinical data expected H1 2024.
Achieved Vertex milestone triggering $17.5M payment; entered license for ENTR-501 with Pierrepont Therapeutics.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Entrada Therapeutics, Inc. reported third quarter ending September 30, 2023 results: revenue $43.7 million, net income $35.5 million.

Period: third quarter ending September 30, 2023
Revenue: $43.7 million
Net income: $35.5 million
Result: reported results

Exact text from the filing

milestones, will be sufficient to fund the Company's operating expenses and capital expenditure requirements through 2025. Collaboration Revenue: Collaboration revenue was $43.7 million for the third quarter of 2023. There was no collaboration revenue in the third quarter of 2022. Research & Development (R&D) Expenses: R&D expenses were $22.2 million for the

View on SEC.gov

44 earnings releases filed in the last 30 days. Browse all earnings releases →

Entrada Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001689375-23-000072

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.